Drug intelligence / Profile preview

NZ-GHMH-01

Development stage: Preclinical
Lead developer: Novones
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

NZ-GHMH-01 is an investigational probiotic combination of two live bacterial strains, *Limosilactobacillus reuteri* DSM 32910 and *Lacticaseibacillus paracasei* DSM 32851. [1-2] It is formulated as an oral capsule and is being evaluated for its potential to improve glucose homeostasis in adults with prediabetes. [2-1, 2] A clinical trial sponsored by Novozymes A/S investigated the probiotic's effect on maintaining healthy blood sugar levels, improving insulin sensitivity, and glycemic control in prediabetic individuals with visceral obesity. [1-3, 2-2, 2] The study was a double-blind, randomized, placebo-controlled trial that compared NZ-GHMH-01 to both a placebo and metformin. [1-3, 2]

Other names: Limosilactobacillus reuteri DSM 32910 + Lacticaseibacillus paracasei DSM 32851

Beyond the preview

Go deeper on NZ-GHMH-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NZ-GHMH-01.

Explore the full profile